Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Abiraterone + Olaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abiraterone||Zytiga||CB7630||Hormone - Anti-androgens 27||Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).|
|Olaparib||Lynparza||AZD2281|KU-0059436||PARP Inhibitor (Pan) 19||Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Abiraterone + Olaparib||Phase II||Actionable||In a Phase II trial, treatment with the combination of Lynparza (olaparib) and Zytiga (abiraterone) resulted in a prolonged median radiographic progression-free survival of 13.8 months, compared to 8.2 months with placebo plus Zytiga (abiraterone), in patients with metastatic castration-resistant prostate cancer (PMID: 29880291; NCT01972217).||29880291|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03732820||Phase III||Abiraterone Abiraterone + Olaparib||Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer||Active, not recruiting|